Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
US11020429B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Nov 4, 2016 |
| Grant date | Jun 1, 2021 |
| Priority date | — |
| Expiry date | Jun 25, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/998
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are cells, e.g., engineered immune cells, expressing recombinant or engineered molecules involved in metabolic pathways, such as those that promote or inhibit one or more metabolic steps, reactions, or pathways, for example, in T cells. Such molecules include those that induce or repress a particular functional outcome or metabolic event, for example, one that promotes differentiation or reprogramming into a particular phenotypic state, such as memory, long-lived, activated or activatable, non-exhausted, phenotype or stem-like phenotype. The cells generally further express an immune receptor, such as an antigen receptor, which may be an engineered receptor, such as a CAR or recombinant TCR, or may be a natural immune receptor. Also provided are cells, such as T cells, expressing such molecules and combinations thereof, compositions comprising such cells, nucleic acids such as vectors encoding the same, and methods of administration to subjects in adoptive cell therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.